Enhancement of ventricular gap-junction coupling by rotigaptide

Cardiovascular Research

Volumn 79, Issue 3, 2008, Pages 416-426

  Lin, Xianming ^a   Zemlin, Christian ^a   Hennan, James K ^b   Petersen, Jørgen S ^c   Veenstra, Richard D ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b PFIZER INC   (United States)

^c Zealand Pharma AS   (Denmark)

Author keywords

Antiarrhythmic agents; Cell communication; Connexins; Gap junctions; Rotigaptide

Indexed keywords

ROTIGAPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL JUNCTION; COMPUTER SIMULATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; DRUG EFFECT; DRUG EFFICACY; ELECTRIC POTENTIAL; HEART ARRHYTHMIA; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART VENTRICLE; KINETICS; MODEL; NEWBORN; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; STEADY STATE; THERAPY EFFECT; WHOLE CELL;

ACTION POTENTIALS; ANIMALS; ANIMALS, NEWBORN; ANTI-ARRHYTHMIA AGENTS; CELL COMMUNICATION; CELLS, CULTURED; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GAP JUNCTIONS; HEART VENTRICLES; KINETICS; MICE; MICE, INBRED C57BL; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; OLIGOPEPTIDES;

EID: 48749096457     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn100     Document Type: Article

References (43)

1. Poelzing S, Akar FG, Baron E, Rosenbaum DS. Heterogeneous connexin43 expression produces electrophysiological heterogeneities across ventricular wall. Am J Physiol Heart Circ Physiol 2004;286:H2001-H2009.
2. Gutstein DE, Morley GE, Vaidya D, Liu F, Chen FL, Stuhlmann H et al. Heterologous expression of gap junction channels in the heart leads to conduction defects and ventricular dysfunction. Circulation 2001;104:1194-1199.
3. Gutstein DE, Danik SB, Lewitton S, France D, Liu F, Chen FL et al. Focal gap junction uncoupling and spontaneous ventricular ectopy. Am J Physiol Heart Circ Physiol 2005;289:H1091-H1098.
4. Xing D, Kjølbye AL, Nielsen MS, Petersen JS, Harlow KW, Holstein-Rathlou NH et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 2003;14:510-520.
5. Herve JC, Dhein S. Pharmacology of cardiovascular gap junctions. Adv Cardiol 2006;42:107-131.
6. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Disc 2006;5:1034-1049.
7. Clark TC, Thomas D, Petersen JS, Evans WH, Martin PEM. The antiarrhythmic pewptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin43. Brit J Pharmacol 2006;147:486-495.
8. Haugan K, Olsen KB, Hartvig L, Petersen JS, Holstein-Rathlou NH, Hennan JK et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Electrophysiol 2005;16:537-545.
9. Haugan K, Marcussen N, Kjølbye AL, Nielsen MS, Hennan JK, Petersen JS. Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 2006;47:236-242.
10. Hennan JK, Swillo RE, Morgan GA, Keith JC Jr, Schaub RG, Smith RP et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther 2006;317:236-243.
11. Kjølbye AL, Haugan L, Hennan JK, Petersen JS. Pharmacological modulation of gap junction function with the novel compound Rotigaptide: a promising new principle for prevention of arrhythmias. Basic Clin Pharmacol Toxicol 2007;101:215-230.
12. Lin X, Gemel J, Beyer EC, Veenstra RD. Dynamic model for ventricular junctional conductance during the cardiac action potential. Am J Physiol Heart Circ Physiol 2005;288:H1113-H1123.
13. Weingart R, Maurer P. Action potential transfer in cell pairs isolate from adult rat and guinea pig ventricles. Circ Res 1988;63:72-80.
14. Kléber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 2004;84:431-488.
15. Nattel S, Maguy A, Le Bouter S, Yeh T-S. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007;87:425-456.
16. Veenstra RD. Voltage clamp limitations of dual whole-cell gap junction current and voltage recordings. I. Conductance measurements. Biophys J 2001;80:2231-2247.
17. Luo C-H, Rudy Y. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ Res 1994;74:1071-1096.
18. Wang LJ, Sobie EA. Mathematical model of the neonatal mouse action potential. Am J Physiol Heart Circ Physiol 2008; Epub ahead of print 11 April 2008.
19. Dhein S. Pharmacology of gap junctions in the cardiovascular system. Cardiovasc Res 2004;62:287-298.
20. Faber GM, Rudy Y. Action potential and contractility changes in. Action potential and contractility changes in [Na(+)](i) overloaded cardiac myocytes: a simulation study. Biophys J 2000;78:2392-2404.
21. Shaw RM, Rudy Y. Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ Res 1997;81:727-741.
22. Luke RA, Saffitz JE. Remodeling of ventricular conduction pathways in healed canine infarct border zones. J Clin Invest 1991;87:11594- 11602.
23. Cabo C, Yao J, Boyden PA, Chen S, Hussain W, Duffy HS et al. Heterogeneous gap junction remodeling in reentrant circuits in the epicardial border zone of the healing canine infarct. Cardiovasc Res 2006;72:241-249.
24. Kléber AG, Riegger CB, Janse MJ. Electrical uncoupling and increase of extracellular resistance after induction of ischemia in isolated, arterially perfused rabbit papillary muscle. Circ Res 1987;61:271-279.
25. Cascio WE, Yang H, Johnson TA, Muller-Borer BJ, Lemasters JJ. Electrical properties and conduction in reperfused papillary muscle. Circ Res 2001;89:807-814.
26. De Mello WC. Effect of intracellular injection of calcium and strontium on cell communication in the heart. J Physiol 1975;250:231-245.
27. De Mello WC. Uncoupling of heart cells produced by intracellular sodium injection. Experentia 1975;31:460-461.
28. Weingart R. The actions of ouabain on intercellular coupling and conduction velocity in mammalian ventricular muscle. J Physiol 1977;264:341-365.
29. Spach MS, Kootsey JM, Sloan JD. Active modulation of electrical coupling between cardiac cells of the dog. A mechanism for transient and steady state variations in conduction velocity. Circ Res 1982;51:347-362.
30. Kléber AG. Consequences of acute ischemia for the electrical and mecjhanical function of the ventricular myocardium. A brief review. Experentia 1990;46:1162-1167.
31. Kjølbye AL, Dikshteyn M, Eloff BC, Deschênes I, Rosenbaum DS. Mantenance of intercellular couopling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans. Am J Physiol Heart Circ Physiol 2008;294:H41-H49.
32. Shibayama J, Lewandowski R, Kieken F, Coombs W, Shah S, Sorgen PL et al. Identification of a novel peptide that interferes with the chemical regulation of connexin43. Circ Res 2006;98:1365-1372.
33. Eloff BC, Gilat E, Wan X, Rosenbaum DS. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. Circulation 2003;108:3157- 3163.
34. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhytmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 2007;115:310-318.
35. Guerra JM, Everett TH, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006;114:110-118.
36. Haugen K, Miyamoto T, Takeishi Y, Kubota I, Nakayama J, Shimojo H et al. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria. Basic Clin Pharmacol Toxicol 2006;99:71-79.
37. Xing D, Kjølbye AL, Petersen JS, Martins JB. Pharmacological stimulation of cardiac gap junction coupling does not affect ischemia-induced focal ventricular tachycardia or triggered activity in dogs. Am J Physiol Heart Circ Physiol 2005;288:H511-H516.
38. Lin X, Crye M, Veenstra RD. Regulation of connexin43 gap junctional conductance by ventricular action potentials. Circ Res 2003;93:e63-e73.
39. Weng S, Lauven M, Schaefer T, Polontchouk L, Grover R, Dhein S. Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation. FASEB J 2002;16:1114- 1116.
40. Axelsen LN, Stahlhut M, Mohammed S, Larsen BD, Nielsen MS, Holstein-Rathlou N-H et al. Identification of ischemia-regulated phosphorylation sites in connexin43: a possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). J Molec Cell Cardiol 2006;40:790-798.
41. Quan W, Rudy Y. Unidirectional block and reentry of cardiac excitation: a model study. Circ Res 1990;66:367-382.
42. Joyner RW, Sugiura H, Tan RC. Unidirectional block between isolated rabbit ventricular cells coupled by a variable resistor. Biophys J 1991;60:1038-1045.
43. Henriquez AP, Vogel R, Muller-Borer BJ, Henriquez CS, Weingart R, Cascio WE. Influence of dynamic gap junction resistance on impulse propagation in ventricular myocardium: a computer simulation study. Biophys J 2001;81:2112-2121.